Skip to main content
. 2023 Mar 21;13(6):1826–1842. doi: 10.7150/thno.82069

Figure 1.

Figure 1

DON ameliorates BLM-induced pulmonary arterial and RV remodeling. A. Study design and scheme timeline. B. Representative images of HE-stained lung sections under a light microscope for each group; the arrow points to pulmonary vessels, and the enlarged vessel is presented in the bottom-right corner (×400 magnification, image size: 715 × 408 μm). C. Statistical analysis of the pulmonary arterial lumen to vessel diameter (n = 6). D. Statistical analysis of the pulmonary arterial WT% (n = 6). E. Statistical analysis of the RVSP (n = 8). F. Representative Masson's trichrome staining of heart samples and echocardiography, respectively, in the parasternal short axis and apical four chamber heart view. G. Quantitative analysis of RVHI (n = 7). H. Statistical analysis of PAAT (n = 7). I: Statistical analysis of PAAT/PET (n = 7). J: Statistical analysis of TAPSE (n = 7). K: Statistical analysis of the survival rate (n = 20). BLM: bleomycin, Ctrl: control, DON: donepezil, HE: hematoxylin and eosin, LV: left ventricle, PAAT: pulmonary arterial acceleration time, PET: pulmonary ejection time, RV: right ventricle, RVHI: RV hypertrophy index, RVSP: right ventricular systolic pressure, S: septum, TAPSE: tricuspid annular plane systolic excursion. WT: wall thickness. *P < 0.05, versus Ctrl group, #P < 0.05, versus BLM group.